Is the business good?
How good a business is BSX?
Boston Scientific earns 8.8% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
8.8%
Return on invested capital · cost of capital 9.0% · 0.20 points below what the capital costs: growth destroys value
- Operating margin
- 20%
Operating margin · Medical Devices median 11% · 12 months to Q2 2026
- Cash conversion
- 0.99×
Cash conversion · 1.40× a year ago · some of the reported profit has not turned into cash yet
- Share count, year on year
- −1.3%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | −0.81% |
| FY2021 | 10% |
| FY2022 | 13% |
| FY2023 | 16% |
| FY2024 | 16% |
| FY2025 | 18% |
Details›
- Gross margin12 months to Q2 2026
- 70%
- Operating margin12 months to Q2 2026
- 20%
- Net margin12 months to Q2 2026
- 17%
- Free cash flow margin
- 17%
- R&D as % of revenue
- 10%
- Revenue, trailing twelve months
- $21.0B
- Free cash flow, trailing twelve months
- $3.63B
- Net income, trailing twelve months
- $3.67B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 8.8%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Medical Devices
Ranks #24 of 35 by Smart Score